Abstract: Gabapentin enacarbil XR is a new extended-release formulation which attempts to overcome the reduced efficacy of shorter-acting gabapentin, with sustained delivery over a 24-hour period. It is a gabapentin prodrug which is efficiently and rapidly converted to gabapentin during active transport throughout the length of the intestine via high-capacity monocarboxylate type 1 nutrient transporters unlike its predecessor, which is absorbed via low-capacity transporters largely confined to the upper intestinal region. Its lack of saturable absorption allows for dose-proportional absorption and hence increased bioavailability. Several clinical trials addressing its efficacy in moderate to severe restless legs syndrome (RLS) demonstrate improvements in the International RLS Rating Scale after a 2-week to 3-month period. Open-label studies of 52 weeks’ duration showed maintenance of symptom reduction with once-daily administration of the extended-release formulation. The most commonly reported treatment-emergent adverse effects were somnolence and dizziness. Although the incidence of emergent adverse effects is high, it is comparable with that of gabapentin. No studies thus far have documented augmentation as an issue, unlike that observed with most dopaminergic agents. In addition, both dopamine precursors and agonists have not been shown to increase slow wave sleep or improve overall sleep architecture consistently despite improvement in the periodic leg movement index, in contrast with gabapentin enacarbil. Presently, gabapentin enacarbil has not been approved by the Therapeutic Goods Administration or Medsafe for use in RLS. The cost of this medication may also be a potential barrier for many patients. Future comparative efficacy studies with gabapentin, first-line dopaminergic agents, rotigotine, being the other once daily RLS medication, and pregabalin, the structural analog of gabapentin, will be necessary.

Keywords: extended-release gabapentin, restless legs syndrome

Introduction

Restless legs syndrome (RLS) affects 4%–14% of the adult population, depending on the rigorousness of the definition applied. It is twice as common in women, and has a prevalence of 2% in the pediatric population. RLS is a sensorimotor disorder, in which there is an irresistible urge to move the leg, although it can progress to involve other parts of the body, including the arms, trunk, and head. Often it is described as unpleasant, creeping, and crawling sensations or paraesthesias deep in the legs. These are particularly problematic during periods of rest, classically relieved by movement and worse in the evenings. The prior three features are also part of the essential diagnostic criteria of RLS alongside the urge to move the legs. Other non-essential but supportive features of RLS include a positive family history, response to dopaminergic agents, and periodic leg movements. Several aspects of a patient’s life can be influenced by RLS,
including difficulty with sleep initiation and maintenance, mood, cognitive function, and quality of life.\textsuperscript{3, 9} While primary (idiopathic) RLS affects the majority of patients with this disorder, secondary RLS can also occur in patients with predisposing conditions, including iron deficiency, chronic renal failure, and pregnancy.\textsuperscript{10–12}

A decision to treat RLS is based mostly on symptom severity, frequency, and impact on quality of life.\textsuperscript{13} An estimated 3\% of patients with RLS are started on treatment at a general practitioner’s office for moderate to severe symptoms.\textsuperscript{14} Sleep diaries and validated symptom rating scales can be utilized to assess the benefits of an intervention compared with baseline.\textsuperscript{15, 16} Both non-pharmacologic and pharmacologic treatment options are employed for the management of RLS. Although there is limited published evidence for the former, there are several non-pharmacological approaches that are utilized for milder RLS. These include partaking in mentally stimulating activities, improving sleep hygiene, lower body resistance training, aerobic exercise, weight loss, and pneumatic compression stockings.\textsuperscript{17–20} A reduction in alcohol, tobacco, and caffeine is also advised.\textsuperscript{21}

With respect to vitamin and mineral supplementation, iron replacement to a goal ferritin of 50 μg/L for patients with iron deficiency (with or without anemia) and treatment of folate deficiency during pregnancy may help alleviate symptoms of RLS.\textsuperscript{15, 22–24} Magnesium is currently being investigated as a potential treatment for RLS, with one small open-label study showing an improvement in symptoms and sleep efficiency. However, a randomized controlled trial in pregnant patients with RLS did not demonstrate relief of symptoms with 360 mg of magnesium daily.\textsuperscript{25, 26}

The first-line pharmacotherapy for RLS is the dopaminergic agents. These include levodopa carbidopa or levodopa benserazide, which are dopamine precursors, as well as several dopamine agonists, such as pramipexole, ropinirole, and rotigotine. While dopamine agonists have a longer duration of action and an estimated 50\% decrease in incidence of augmentation in comparison with dopamine precursors, one third of patients will continue to develop progressive worsening of symptoms on therapy.\textsuperscript{27, 28} With augmentation, symptoms start to occur earlier in the day, become more severe in intensity and may affect other parts of the body, including the arms and trunk.\textsuperscript{29} The pathophysiology of augmentation remains unclear and treatment is challenging, being largely based on clinical consensus and expert opinion.\textsuperscript{29} Impulse control disorders, including gambling and compulsive shopping, can also occur in up to 17\% of patients, much like in Parkinson’s, which can result in serious social consequences.\textsuperscript{30}

Rotigotine is a long-acting transdermal agent with good 5-year efficacy and tolerability and may be particularly useful for patients with both daytime and night-time symptoms.\textsuperscript{31} However, in a recent 5-year, open-label extension study, 13\% of patients developed clinically significant augmentation and 58\% developed mostly mild to moderate skin reactions at the application site.\textsuperscript{31} In addition, it is currently more expensive than other dopamine agonists.

Second-line agents include low potency opioids, benzodiazepines, and gabapentin. With no controlled trials on opioids and limited randomized controlled trials on benzodiazepines, these agents presently remain off-label therapeutic options.\textsuperscript{32, 33} Early morning sedation, tolerance, and dependence are potential challenges with these medications. Anticonvulsants like gabapentin are particularly useful for painful RLS.\textsuperscript{34} A double-blind, randomized, placebo-controlled crossover study in 24 RLS subjects showed a significant reduction in RLS severity with gabapentin when dosed twice a day.\textsuperscript{34} In addition, small clinical trials have also demonstrated better RLS symptom relief with gabapentin than with levodopa in hemodialysis patients and comparable improvements with ropinore.\textsuperscript{35, 36} The side effects are generally mild to moderate in nature, and include dizziness, somnolence, and peripheral edema. However, its efficacy is limited by its short half-life.\textsuperscript{34} Another anticonvulsant being investigated for RLS is pregabalin, a gabapentin analog which acts on the α2δ subunit of the voltage-dependent Ca\textsuperscript{2+} channel like gabapentin. There are currently two published, double-blind, randomized, controlled studies lasting 6–12 weeks, showing a reduction in RLS symptoms over placebo, but future comparative efficacy and longer-term studies are necessary.\textsuperscript{37, 38}

In April 2011, the US Food and Drug Administration approved a new long-acting gabapentin (gabapentin enacarbil XR, Horizant\textsuperscript{TM}) which attempts to overcome the reduced efficacy of shorter-acting gabapentin, with sustained delivery over a 24-hour period. Presently, medications listed for the management of RLS by the Therapeutic Goods Administration in Australia are pramipexole, ropinirole, and rotigotine. New Zealand’s Medsafe has approved pramipexole for RLS. This article reviews the current literature on the pharmacology, pharmacokinetics, and clinical trials on gabapentin enacarbil and discusses its practical implications in the management of RLS.

**Pharmacology and pharmacokinetics**

Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the human central nervous system.\textsuperscript{39}
Gabapentin is a GABA analog but is not believed to act on the same receptors. Instead, it acts on the α2δ subunit of the voltage-dependent Ca2+ channel. This interaction reduces calcium influx into the presynaptic nerve terminals and results in inhibition of excitatory neurotransmitter release. The drug is absorbed via low-capacity transporters in the upper intestinal region. These transporters become saturated at the recommended doses, and increasing doses beyond the suggested dose range results in decreased bioavailability. A 600 mg dose had an average bioavailability of 50%, whereas daily 3600 mg doses resulted in a reduced bioavailability of 40%. Wide variation in interpatient bioavailability may also be observed. Gabapentin has a half-life of 5–7 hours and is excreted by the kidney without appreciable metabolism.

Gabapentin enacarbil XR is a gabapentin prodrug which is efficiently and rapidly converted to gabapentin during active transport throughout the length of the intestine via high-capacity monocarboxylate type 1 nutrient transporters. An open-label, single-center Phase I study of 14 healthy male volunteers demonstrated up to 85% recovery of a radioactive dose in urine within 24 hours of 14C-labeled gabapentin enacarbil dosing. Levels of intact prodrug were low and transient. Unlike gabapentin, its lack of saturable absorption allows for dose-proportional absorption. In a study performed in healthy volunteers, extended-release gabapentin had a bioavailability of 83% and 72%, respectively, at doses of 350 mg and 2100 mg, whereas bioavailability was reduced at 65% and 27%, respectively, with doses of 200 mg and 1400 mg of gabapentin. Consuming the drug with meals, regardless of fat or caloric content, further increased its bioavailability in a small randomized, cross-over, open-label study and several Phase I trials. In patients with renal impairment, dosage adjustment is necessary because its elimination is proportional to creatinine clearance. No dose adjustments were needed when coadministered with either 500 mg naproxen twice daily or 400 mg cimetidine four times a day. Like gabapentin enacarbil, naproxen is also a substrate for the high-capacity monocarboxylate type 1 nutrient transporter in the intestine and cimetidine is a substrate for the organic cation transporter in the kidney, by which elimination of extended-release gabapentin occurs. Hence no clinically relevant pharmacokinetic interactions are expected between gabapentin enacarbil and other substrates of these transporters. Overall, the improved pharmacokinetics of this extended-release formulation compared with gabapentin thus allows for its once-daily administration.

**Clinical trials**

**Efficacy**

There are currently seven published clinical trials which address the efficacy of gabapentin enacarbil. The study characteristics, primary endpoints, and results of these trials are summarized in Table 1. Five of these are double-blind, placebo-controlled randomized trials with study sizes of 38–327 participants. All subjects experienced moderate to severe RLS and were either treatment-naive or discontinued treatment at least 2 weeks prior to the study. The duration of the interventions were 14 days, 12, 14, and 24 weeks. Participants were advised to take the study drug at 5 pm with food in all but one study due to its previously published improved bioavailability. Kushida et al split the drug dosing (5 pm and one hour before bedtime), testing a higher dose of 1800 mg daily, whereas other studies used either 600 mg or 1200 mg daily. The primary endpoints for both 14-day studies were the change in baseline International RLS Rating Scale (IRLS) at day 14. The rating scale is a validated 10 question rating scale to be filled out by patients, published by the International RLS study group; this helps grade subjective RLS symptoms and may be particularly useful when assessing treatment effects. The other three studies also included investigator rated Clinical Global Impression-Improvement (CGI-I) in addition to the IRLS.

Four studies showed a significant improvement in their primary outcome measures, but the study by Walters et al only showed a difference with the 1200 mg/day dose and not with 600 mg/day. In contrast, the larger (n = 95 versus 325) and longer (14 days versus 12 weeks) study by Lee at al did show a significant difference with 600 mg/day dosing. Interestingly, improvement in the coprimary endpoints were observed even at 2 weeks into the study. The fifth study was undertaken in two parts. The single-blind phase identified the responders to the drug, who then subsequently entered the double-blind phase of the study. Fewer relapses (9% versus 23%) were observed in patients taking the active study drug in comparison with placebo. It is unclear if the proportion of relapses in the placebo arm would have increased further beyond the 12-week duration of this double-blind phase.

The last two studies are both 52-week open-label studies using gabapentin enacarbil 1200 mg/day. The first is an extension study undertaken by Ellenbogen et al. Participants (n = 573) were enrolled from several prior gabapentin enacarbil studies. They consumed the study drug at 5 pm with food. The study had similar coprimary outcomes to those mentioned above and showed maintenance of symptom...
### Table 1 Efficacy and tolerability clinical trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Intervention</th>
<th>Primary endpoints</th>
<th>Results and adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walters et al&lt;sup&gt;50&lt;/sup&gt;</td>
<td>n = 95</td>
<td>Double-blind RCT GEn 600 or 1200 mg versus placebo</td>
<td>Change in baseline IRLS total score at day 14</td>
<td>Greater reduction in IRLS with GEn 1200 mg/day (~16.1 versus −8.9, adjusted mean difference −7.2, P &lt; 0.0001)</td>
</tr>
<tr>
<td></td>
<td>Treatment-naive patients</td>
<td>Moderate to severe RLS taken at 5 pm daily with food Duration 14 days</td>
<td></td>
<td>No difference with GEn 600 mg/day Improvement in CGI-I responses, overall sleep quality, number of nights with RLS symptoms, hours awake per night, mood, and severity of RLS symptoms on GEn 1200 mg/day</td>
</tr>
<tr>
<td>Kushida et al&lt;sup&gt;52&lt;/sup&gt;</td>
<td>n = 38</td>
<td>Double-blind crossover RCT GEn 1800 mg/day versus placebo</td>
<td>Change in baseline IRLS total score at day 14</td>
<td>Greater reduction in IRLS with GEn (~12.1 versus −1.9; P &lt; 0.0001)</td>
</tr>
<tr>
<td></td>
<td>Treatment-naive patients</td>
<td>Moderate to severe RLS 1200 mg taken 1 hour before bedtime GEn titrated to target dose over 4 days Duration 14 days each with 7-day washout period between arms</td>
<td></td>
<td>Improvement in CGI-I responses, sleep quality RLS severity, and hours awake per night Documented improvement in sleep architecture by PSG with reduced stage I sleep and increased slow-wave sleep 85% of subjects reported “much improved” or “very much improved” symptoms versus placebo (15%) Somnolence (30% versus 3% with placebo) and dizziness (28% versus 6% with placebo) Dose decreased or maintained at 1200 mg/day in a total of 6 subjects</td>
</tr>
<tr>
<td>Kushida et al, PIVOT RLS-I study&lt;sup&gt;51&lt;/sup&gt;</td>
<td>n = 222</td>
<td>Double-blind multicenter RCT GEn 1200 mg/day versus placebo</td>
<td>Change in baseline IRLS total score at 12 weeks and investigator-rated CGI-I</td>
<td>Greater reduction in IRLS with GEn (~13.2 versus −8.8; mean treatment difference −4, P = 0.0003) and more treatment responders (76% versus 39%; P &lt; 0.0001) according to CGI-I Significant treatment effects for both coprimary endpoints were observed at week 1 Somnolence (27% versus 8% with placebo) and dizziness (20% versus 5% with placebo)</td>
</tr>
<tr>
<td></td>
<td>Moderate to severe RLS</td>
<td>Prior RLS treatment discontinued at least 2 weeks prior to baseline assessment</td>
<td></td>
<td>Responders entered double-blind phase (n = 194 or 88%)</td>
</tr>
<tr>
<td>Bogan et al, PIVOT RLS maintenance study&lt;sup&gt;53&lt;/sup&gt;</td>
<td>n = 327</td>
<td>Multicenter RCT GEn 1200 mg/day versus placebo</td>
<td>Responders in single-blind phase (ie, improved IRLS total score and CGI-I) entered double-blind study Proportion of patients with relapse (increase &gt; 6 points in IRLS total score and rating of “much worse” or “very much worse” on investigator-rated CGI-I)</td>
<td>Less relapse with GEn (9% versus 23% with placebo, odds ratio 0.35, 95% confidence interval 0.2–0.8, P = 0.02)</td>
</tr>
<tr>
<td></td>
<td>Treatment-naive or prior RLS medications discontinued within the month</td>
<td>Taken at 5 pm with food Duration 24 weeks Double-blind phase (n = 194) GEn 1200 mg/day versus placebo (with 2-week taper in placebo group) Taken at 5 pm with food Duration 12 weeks</td>
<td></td>
<td>Long-term tolerability for up to 9 months of treatment</td>
</tr>
</tbody>
</table>
Lee et al, PIVOT RLS-II study 34

Double-blind multicenter RCT
- GEn 1200 mg or 600 mg versus placebo
- Taken at 5 pm with food
- Duration 12 weeks

Ellenbogen et al 45

Open-label extension study
- GEn 1200 mg/day
- Taken at 5 pm with food
- Duration 52 weeks

Inoue et al 52–54

Multicenter open-label study
- GEn 1200 mg/day
- Taken after evening meal
- Duration 52 weeks

Abbreviations: CGI-I, Clinical Global Impression-Improvement; GEn, gabapentin enacarbil; IRLS, International RLS Rating Scale; RCT, randomized controlled trial; RLS, restless legs syndrome.

Greater reduction in IRLS (adjusted mean treatment difference -3.5, P = 0.0015 and -4.3, P < 0.0001) and increased treatment responders according to CGI-I (78% versus 45% with placebo; 73% versus 45% with placebo) with GEn 1200 and 600 mg/day, respectively.

Somnia (18% versus 22%) and dizziness (24% versus 10%) were the most commonly reported adverse effects, percentages are for 1200 and 600 mg GEn, respectively.

Inoue et al study, the prevalence of dizziness (0.4 weeks 42%, versus week 52 1.4%) gradually decreased over time. The majority of patients reported these adverse effects within the first 2–4 weeks of the trial. A median duration of 42 days (versus 30 days with placebo and 13 days (versus 26 days with placebo) was reported for somnolence and dizziness. While there was a high incidence of treatment-emergent adverse effects (39%–81%), these were generally of mild to moderate intensity and of similar proportion to gabapentin enacarbil of up to 6000 mg/day in healthy volunteers (51%–82%) (45). The majority of patients reported these adverse effects within the first 2–4 weeks of the trial (35%). A median duration of 42 days (versus 30 days with placebo and 13 days (versus 26 days with placebo) was reported for somnolence and dizziness. While there was a high incidence of treatment-emergent adverse effects (39%–81%), these were generally of mild to moderate intensity and of similar proportion to gabapentin enacarbil of up to 6000 mg/day in healthy volunteers (51%–82%) (45). The majority of patients reported these adverse effects within the first 2–4 weeks of the trial (35%).

In all studies shown in Table 1, the most commonly reported treatment-emergent adverse effects were related to the study drug and placebo. Other notable adverse effects include nasopharyngitis, nausea, fatigue, sleep attacks, headache, insomnia, decreased libido, and diarrhea. While there was a high incidence of treatment-emergent adverse effects (39%–81%), these were generally of mild to moderate intensity and of similar proportion to gabapentin enacarbil of up to 6000 mg/day in healthy volunteers (51%–82%) (45). The majority of patients reported these adverse effects within the first 2–4 weeks of the trial (35%).

In all studies shown in Table 1, the most commonly reported treatment-emergent adverse effects were related to the study drug and placebo. Other notable adverse effects include nasopharyngitis, nausea, fatigue, sleep attacks, headache, insomnia, decreased libido, and diarrhea. While there was a high incidence of treatment-emergent adverse effects (39%–81%), these were generally of mild to moderate intensity and of similar proportion to gabapentin enacarbil of up to 6000 mg/day in healthy volunteers (51%–82%) (45). The majority of patients reported these adverse effects within the first 2–4 weeks of the trial (35%).
Several secondary endpoints assess additional patient-focused perspectives. In general, improvements in sleep quality, number of nights with RLS symptoms, hours awake as well as frequency of awakenings at night, mood, and patient rated CGI-I have been documented.50-52,54,56 Kushida et al further showed an improvement in sleep architecture by polysomnography, with reduced stage 1 sleep and increased slow wave sleep. In the same study, 85% of subjects reported feeling “much improved” or “very much improved” compared with placebo (15%). Patient symptom diaries also documented a reduction in RLS intensity or RLS symptoms altogether.54 Overall, gabapentin enacarbil is generally safe and well tolerated without significant augmentation.

Practical implications

The improved pharmacokinetics of gabapentin enacarbil over gabapentin has been shown in several Phase I trials and animal studies, with its non-saturable absorption throughout the entire length of the intestine.44,46,57 Nevertheless, there have thus far been no comparative efficacy studies using these two medications. Hence, the practical benefit of its improved bioavailability compared with gabapentin remains a theoretical advantage at present.

Several Phase II and III studies using gabapentin enacarbil 600–1800 mg/day have shown reduced RLS severity by the IRLS and therapeutic benefit from a physician’s perspective based on the CGI-I. There have also been two longer studies documenting continued benefit of the drug compared with placebo over 52 and 64 weeks. Neither of these studies documented a reduction in RLS intensity or RLS symptoms altogether.54 Overall, gabapentin enacarbil is generally safe and well tolerated without significant augmentation.

Disclosure

The authors report no conflicts of interest in this work.

References


